 Hi, I'm Claudia and this is a summary on our publications on the implementation of volume staging for AVM treatments on a linoleic using VMA. Volume staging is a stereotactic radio surgery strategy used for inoperable AVMs in the brain. The main objective of volume staging is to treat smaller volumes that allow for delivering higher doses to the AVM while meeting the normal brain constraints, mainly the volume that receives 12 brains or more. So instead of treating the whole volume, stages are treated in separate SRS sessions resulting in lower normal brain B12 brains. Since we found little evidence on the use of Linux systems for volume staging, we studied the feasibility of implementing it on our variant true beam SRS system. We prepared volume stage plans that we call PTV VMA plans as they use the 1mm margin established for cranial SRS. We also calculated AVM VMA plans with 0mm margin so we could make comparisons to publish data from gammon F plans. Finally, we evaluated the dosimetric accuracy of our lunatic base volume staging by delivering our PTV VMA plans to radiocromic film and a diamond detector placed at the junction between the two stages. Select the 10 patients with the range of AVM sizes and locations to create volume stage plans. The stages are shown in red and yellow. The brains stem in green and optics in blue. AVM volumes range from 2.2 to 34.6 cc and we're all divided into approximately equal volume stages. For all plans, we used a single fraction of 20 grays for all stages. We allowed the maximum dose to go as high as possible, which is the gammon F plans. We also created control structures to encourage a sharp dose falloff from the PTV margin and maximum dose is in the middle of the stage. The structure at the junction was also used to minimize the dose in this region for the sound plans. Radiocromic film was used in two ways to verify the treatment plan in dose and to assess the positional errors that could arise from setting up a patient twice for the second stage. This was done by exposing one film to both stages after one convene setup and another film was set up twice by removing the phantom from the couch and starting the setup process again for the second stage. We did film comparison and gammon analysis for film to film and for each film to treatment plan in dose. Moving on to some of our results, PTV VMA plans show that on average, the 312 bray was increased by almost 50% with respect to the ADM plans. PTV maximum dose was also higher, conformity for each target improved slightly as expected with the larger one. Normal bray maximum dose was also increased. Please refer to our publication for further results. Gammon analysis was done with film QA Pro. We used a one millimeter distance to agreement criteria since that is our margin and up to five percent for the TPS dose comparison. We also qualitatively evaluated the profiles isomaps and isopropyls. Films of film gamma analysis are all above 90% for 2% one millimeter and film to TPS dose above 90% for 5% and one millimeter. Film results show that setting up the phantom twice did not introduce additional errors. Point dose verification resulted in an average percent difference to TPS point dose at the isocenter of minus 0.6%. The maximum percent difference of 3.98%. We believe volume staging is feasible using DMACC. Additional stages may need to be considered for AVM volumes of up to 20 CCs. They may need to be combined with fractionated SRS for best normal braying sparing. Ideally, minimizing the margin required could lead to improving both fractionated SRS and volume staging. This may require technical advances in linear mechanical accuracy and a stringent quality control program. Thanks very much for watching and you can find our JANCMP publication here.